Nov 2026Clinuvel · CUV107
Pivotal vitiligo trial (CUV107) set to begin
The confirmatory study meant to underpin regulatory filings across Europe, North America and Africa.
Regulatory watch
On the docket.
A living scoreboard for the question this whole site is watching: whether legitimate melanocortin photoprotection reaches people faster than the gray market can sell the counterfeit. The dated catalysts ahead, the ones already settled, and where Melanotan II legally stands right now.
- Approved / advancing. A legitimate melanocortin drug moving forward.
- Restricted. Melanotan II being walled off further.
- Open question. A pending decision worth watching.
On the calendar
Dated decisions and readouts still ahead, soonest first.
Dec 2026Clinuvel · CUV105
Phase III vitiligo readout for afamelanotide
Topline from the 200-patient CUV105 trial of SCENESSE in vitiligo — the approved MC1R agonist reaching for its second indication. A positive result widens the beachhead.
~ Feb 2027FDA · PCAC
Advisory committee weighs Melanotan II for the compounding list
The FDA’s Pharmacy Compounding Advisory Committee is due to consider whether MT-II can move off the restricted Category 2 list and become compoundable. The first time its U.S. legitimacy is formally on a calendar — and the single most consequential date here.
Already settled
The milestones that shaped the picture above, most recent first.
Jul 2026Health Canada
SCENESSE approved for EPP in Canada
Afamelanotide adds another country — the first systemic photoprotectant keeps spreading through the front door.
27 Feb 2026HHS · FDA
Peptide reshuffle — Melanotan II stays restricted
HHS moved roughly 14 of 19 restricted peptides back toward the compoundable Category 1; Melanotan II was among the ~5 held back. The door stayed shut.
Feb 2026TGA · Australia
Australia reclassifies MT-II to Schedule 9 — the strictest in the world
Placed alongside heroin and LSD; possession without a research licence becomes a criminal offence. Triggered by 89 adverse-event reports (2022–25), including two melanoma cases within 18 months of use.
Jan 2026Tanabe · MT-7117
Oral MC1R agonist posts positive Phase 3
Dersimelagon — a once-daily pill, not an implant — hit its endpoints in EPP and X-linked protoporphyria. Melanocortin photoprotection escaping the needle is the clearest sign yet the class is advancing.
23 Sep 2025EMA · EU
EMA approves year-round SCENESSE dosing
Europe widens the approved use of the first systemic photoprotectant.
Sep 2023FDA
MT-II placed in compounding Category 2
Designated a bulk substance that “may present significant safety risks” — which is what closed the compounding door in the first place.
8 Oct 2019FDA
FDA approves SCENESSE (afamelanotide) for EPP
The first melanocortin agonist approved in the U.S. for a photoprotective use. Proof the approval door opens.
22 Dec 2014European Commission
EU approves SCENESSE — the world’s first systemic photoprotectant
Afamelanotide authorised for EPP under exceptional circumstances; the class’s first market approval anywhere.
Where Melanotan II stands
The unapproved compound, jurisdiction by jurisdiction.
United States
Unapproved · not compoundableNo approved indication; Category 2, so licensed pharmacies can’t compound it; illegal to market for human use. The FDA has sent warning letters to distributors. Compounding status under review in 2027.
United Kingdom
Illegal to sell · legal to possessAn unlicensed medicine the MHRA bars from sale — sold instead as a “cosmetic” nasal spray through a gap between the rulebooks. Selling is illegal; using is not.
Australia
Schedule 9 · prohibitedSince Feb 2026, the strictest classification there is — the same schedule as heroin and LSD. Possession without a research licence is a criminal offence. The toughest market in the world for MT-II.
EU & Nordics
Unapproved · banned as cosmeticNo approved indication anywhere in the EU; banned as a cosmetic in Denmark and others; Ireland’s HPRA warns it is not authorised to treat anything.
The approved side
The counterweight to all that restriction: the legitimate melanocortin agonists that reached patients the right way — and the pipeline behind them.
Afamelanotide (SCENESSE)
MC1R agonist · subcutaneous implant
Approved for EPP in the EU (2014), U.S. (2019), Australia (2020), Israel, and Canada (2026). Now in Phase III for vitiligo, with a readout due Dec 2026.
Dersimelagon (MT-7117)
MC1R agonist · once-daily oral pill
Positive Phase 3 in EPP and X-linked protoporphyria (Jan 2026); regulatory filings expected to follow. The first oral entrant in the class — no needle, no implant.
The through-line: as the legitimate technology keeps advancing — approvals, new indications, an oral entrant — Melanotan II keeps getting walled off further. Those two trends are the whole story. For how a legitimate melanocortin sun drug actually reaches Americans, readThe three doors; for the gray market it competes with, The Barbie drug; for the full arc, the timeline.